Zai Lab Ltd ADR Repr 1 Shs ZLAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
-
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
-
Zai Lab Announces Participation in September Investor Conferences
-
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
-
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
-
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
-
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
-
Airbnb, Tesla stocks rise, Manchester United, Softbank shares fall and other stocks on the move
Trading Information
- Previous Close Price
- $24.62
- Day Range
- $24.96–26.42
- 52-Week Range
- $13.48–31.22
- Bid/Ask
- $26.36 / $26.66
- Market Cap
- $2.63 Bil
- Volume/Avg
- 705,851 / 633,153
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 2,175
- Website
- https://www.zailaboratory.com
Comparables
Valuation
|
Metric
|
ZLAB
|
09969
|
06160
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.67 | 1.70 | 7.81 |
Price/Sales | 7.94 | 13.68 | 8.37 |
Price/Cash Flow | — | — | — |
Price/Earnings
ZLAB
09969
06160
Financial Strength
|
Metric
|
ZLAB
|
09969
|
06160
|
|---|---|---|---|
Quick Ratio | 2.81 | 3.74 | 1.64 |
Current Ratio | 3.46 | 3.82 | 1.98 |
Interest Coverage | — | −25.88 | — |
Quick Ratio
ZLAB
09969
06160
Profitability
|
Metric
|
ZLAB
|
09969
|
06160
|
|---|---|---|---|
Return on Assets (Normalized) | −22.08% | −4.69% | −2.03% |
Return on Equity (Normalized) | −27.96% | −6.63% | −3.24% |
Return on Invested Capital (Normalized) | −31.10% | −7.87% | −4.24% |
Return on Assets
ZLAB
09969
06160
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dzfjkmcth | Wlzh | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dlmbzrkx | Hkzpd | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gwmryhhs | Lcccjz | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gdqdqnwrl | Whvtmh | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Jqstmsr | Fjvvn | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Nplngxfg | Vzxj | $29.2 Bil | |||
| Moderna Inc
MRNA
| Bcqlktbr | Vhkq | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Pfmfsld | Fjzlx | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Thhcvdyf | Djbflp | $13.2 Bil | |||
| Incyte Corp
INCY
| Njqvdyfkw | Xqcqbtr | $13.0 Bil |
United States